When will the question of reversing losses be pressed tonghua dongbao pharmaceutical claims that sales of insulin analogs have increased somewhat | Direct hit earnings conference

① During the performance meeting, some investors asked when Tonghua Dongbao will be able to break out of losses. Chairman Li Jiahong said that the company's performance is expected to recover and grow further; ② with the implementation of the Q3 insulin collection renewal in various provinces and cities, the company doubled its sales volume of insulin analogs; ③ during the performance meeting, the company also answered questions such as increased sales expenses and slow progress of construction projects under construction.

cls.cnNov 18 07:49 ET

lingyuan iron & steel: Supply and demand imbalance has not been eased yet, the industry still needs to reduce overcapacity, control costs, and increase added value | Directly hit earnings conference

①The company recorded a loss of 0.841 billion yuan in the third quarter. Chairman Zhang Peng stated that the imbalance between supply and demand in the industry has not yet eased, and the future steel industry still needs to achieve sustainable development through capacity reduction, cost control, and increasing product added value. ②The actual controlling shareholder of the company will change from Chaoyang City State-owned Assets Supervision and Administration Commission to central enterprise Ansteel Group. The company expects that the governance system will be optimized, information systems upgraded, and synergy achieved in the business sector.

cls.cnNov 8 09:13 ET

Securing the indication of the world's first long-acting growth hormone ISS globally, is there a solution to the situation of both revenue and net profit decline at Changchun High-tech Industries? | Announcement for quick reading

①On the 5th, changchun high-tech industries announced that its long-acting growth hormone has been approved for ISS indication. In August of this year, this variety was also approved for the growth disorder in girls with gonadal dysgenesis (Turner syndrome); ②In the first three quarters of this year, changchun high-tech industries' performance and profitability both declined. Whether the main products that have been on the market for 10 years can have new sales volume is widely watched.

cls.cnNov 5 09:31 ET

Investment income boosts gd power development's performance in the first three quarters, while Q3 revenue and net profit both declined year-on-year. | Express announcement

①Benefiting from investment income, gd power development earned over 9 billion yuan in profits in the first three quarters, a year-on-year increase of over sixty percent; ②Daxingchuan Power Plant recognized an impairment provision of over 0.8 billion yuan, and the company's non-GAAP net profit in the first three quarters decreased by over ten percent.

cls.cnOct 24 09:55 ET

The performance decline continues, tonghua dongbao pharmaceutical's Q3 sales expenses exceed 0.3 billion yuan|interpretations

Due to factors such as a significant decrease in revenue and the termination of research and development pipelines, tonghua dongbao pharmaceutical handed in a loss-making third-quarter report. From the perspective of Q3 performance, the company's revenue shows a certain recovery trend, but the escalating sales expenses quarter by quarter have resulted in a situation of "increased revenue without increased profits".

cls.cnOct 24 09:02 ET

The decline in product price spread dragged down Hengli Petrochemical's Q3 net income to 1.09 billion, a sharp 59% year-on-year decrease. | Financial Report Watch

In the third quarter, hengli petrochemical's earnings per share were 0.16 yuan, a year-on-year decrease of 57.89%. In the third quarter, hengli petrochemical's profit and earnings per share both fell by nearly 60%, mainly due to a year-on-year decrease in product price differentials in the quarter, leading to a decrease in quarterly profit.

wallstreetcnOct 24 08:53 ET